Manisha Shah H. MD

Manisha Shah H. MD
ProfessorCollege of Medicineshah.171@osu.edu
A441 Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-293-8629Fax: (614) 293-4372
  • Translational Therapeutics

General Research Interest

Clinical research in Neuroendocrine cancers, Thyroid cancers and Adrenal Cancers.

Research Description

Dr. Shah's research focuses on discovering new targeted therapies for patients with Neuroendocrine cancers, Thyroid cancers and Adrenal Cancers. Dr. Shah's lab offers phase II-III clinical trials in these types of cancers, conducts pre-clinical studies to learn types of drugs and combination of drugs, and apply that knowledge to design clinical trials. They also perform several tests on tumor genetics, tumor imaging, pharmacokinetics and pharmacodynamics of study drugs as part of our clinical trials.

Transinstitutional Work

We collaborate with other centers to perform clinical trials in Neuroendocrine cancers, Thyroid cancers and Adrenal Cancers.

Current Publications

  • Hobday TJ, Qin R, Reidy-Lagunes D, Moore MJ, Strosberg J, Kaubisch A, Shah M, Kindler HL, Lenz HJ, Chen H, Erlichman CMulticenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.J Clin Oncol in press 12/8/2014
  • Van Loon K, Zhang L, Keiser J, Carrasco C, Glass K, Ramirez MT, Bobiak S, Nakakura EK, Venook AP, Shah MH, Bergsland EKBone metastases and skeletal-related events from neuroendocrine tumors.Endocr Connect in press 11/27/2014
  • Kavecansky J, Wei L, Caronia L, Ramirez MT, Bloomston M, Shah MHBone Metastases in Well-to-Moderately Differentiated Neuroendocrine Tumors: A Single Institutional Review From the Ohio State University Medical Center.Pancreas in press 11/19/2014
  • Lerario AM, Worden FP, Ramm CA, Hasseltine EA, Stadler WM, Else T, Shah MH, Agamah E, Rao K, Hammer GDThe combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.Horm Cancer 5 232-9 8/1/2014
  • Haraldsdottir S, Shah MHNew era for treatment in differentiated thyroid cancer.Lancet 384 286-8 7/26/2014
  • Haraldsdottir S, Shah MHAn update on clinical trials of targeted therapies in thyroid cancer.Curr Opin Oncol 26 36-44 1/1/2014
  • Sherman SI, Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin BCabozantinib in progressive medullary thyroid cancer.J Clin Oncol 31 3639-46 10/10/2013
  • Arrese D, McNally ME, Chokshi R, Feria-Arias E, Schmidt C, Klemanski D, Gregory G, Khabiri H, Shah M, Bloomston MExtrahepatic disease should not preclude transarterial chemoembolization for metastatic neuroendocrine carcinoma.Ann Surg Oncol 20 1114-20 4/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu